Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957852 | 0.82 | TRPV1 (0.41) | TRPV1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL6958627 | 0.82 | TRPV1 (0.41) | TRPV1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL4644110 | 0.79 | TRPV1 (0.40) | TRPV1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL8615203 | 0.73 | TRPV1 (0.34) | TRPV1 | |
| SCHEMBL5916881 | 0.72 | TRPV1 (0.45) | TRPV1 | |
| SCHEMBL23045125 | 0.71 | CHRM3 (0.42) | TRPV1 | |
| SCHEMBL5352937 | 0.71 | CHRM3 (0.42) | TRPV1 | |
| SCHEMBL31284731 | 0.71 | EPAS1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL4372391 | 0.71 | TRPV1 (0.36) | TRPV1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL3424340 | 0.71 | TRPV1 (0.36) | TRPV1CYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| CN-118812481-A | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| EP-4019485-B1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410989-A2 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-114206847-B | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| WO-2021039023-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | 持田製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| EP-1883632-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006116563-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | COASY, NAAA, AADAC | TRPV1 2623/4885CYP1A2 88/4885CYP11B1 67/4885 |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | TRPV1 2623/4885CYP1A2 88/4885CYP11B1 67/4885 |
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | TRPV1 2623/4885CYP1A2 88/4885CYP11B1 67/4885 |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | TRPV1, HRH2, TRPA1 | TRPV1 1/4885CYP1A2 629/4885CYP11B1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.